{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T20:23:11Z","timestamp":1792959791042,"version":"4.5.0"},"reference-count":89,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medizinische Hochschule Hannover (MHH)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Stem Cell Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Severely impaired mucociliary airway function is the primary pathomechanism in Cystic Fibrosis (CF) lung disease. Despite significant advances in CF therapy, there is still a critical need for alternative, individualized treatment options, especially for patients with untreatable CFTR mutations. Although intestinal organoids and primary airway cells are widely used as preclinical models of CF, both systems exhibit limitations with regard to the proper modelling of mucociliary clearance or the availability of sufficient cell quantities. Patient-specific human induced pluripotent stem cells (hiPSCs) are a promising alternative due to their unlimited expansion potential and capacity to differentiate into airway epithelia. However, cellular inhomogeneities in iPSC-derived airway cultures complicated conventional assays that determine CFTR function such as Ussing chamber measurements, and a comprehensive demonstration of CF pathophysiology in hiPSC-derived airway models has been largely lacking. This study provides comprehensive data demonstrating very similar gene expression, (ultra)structure and CFTR function in CF iPSC-derived airway (iALI) and primary airway (pALI) cultures. Addressing current limitations, we have implemented a sensitive, straightforward, and automatable ciliary beat frequency (CBF) assay, which is largely unaffected by inhomogeneities and directly reflects disturbed mucus viscosity and mucociliary transport in CF lung disease. Electron microscopy images confirmed the disease phenotype showing a highly dense and dehydrated mucus layer on top of CF iALI cultures. Furthermore, established CFTR modulator drugs partially rescued the disease phenotype in CF iALI cultures, which validated the utility of iALI cultures as a scalable, patient-specific platform for CF research and personalized drug development.<\/jats:p>","DOI":"10.1186\/s13287-025-04737-0","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:41:38Z","timestamp":1761007298000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Human induced pluripotent stem cells for in vitro modeling of impaired mucociliary clearance in cystic fibrosis lung disease"],"prefix":"10.1186","volume":"16","author":[{"given":"Mark-Christian","family":"Klassen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Bal\u00e1zs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janina","family":"Z\u00f6llner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Cleve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurien","family":"Czichon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"von Schledorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Hegermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janna C.","family":"Nawroth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doris","family":"Roth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mia","family":"Mielenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silke","family":"Hedtfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frauke","family":"Stanke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tihomir","family":"Rubil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Ius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danny","family":"Jonigk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W.","family":"Hanrahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjang","family":"Ruhparwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Olmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus A.","family":"Mall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia","family":"Merkert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,21]]},"reference":[{"issue":"3","key":"4737_CR1","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.jcf.2022.01.009","volume":"21","author":"J Guo","year":"2022","unstructured":"Guo J, Garratt A, Hill A. Worldwide rates of diagnosis and effective treatment for cystic fibrosis. J Cyst Fibros. 2022;21(3):456\u201362.","journal-title":"J Cyst Fibros"},{"issue":"4922","key":"4737_CR2","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1126\/science.2570460","volume":"245","author":"B Kerem","year":"1989","unstructured":"Kerem B, et al. Identification of the cystic fibrosis gene: genetic analysis. Science. 1989;245(4922):1073\u201380.","journal-title":"Science"},{"issue":"4922","key":"4737_CR3","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1126\/science.2475911","volume":"245","author":"JR Riordan","year":"1989","unstructured":"Riordan JR, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science. 1989;245(4922):1066\u201373.","journal-title":"Science"},{"issue":"4922","key":"4737_CR4","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1126\/science.2772657","volume":"245","author":"JM Rommens","year":"1989","unstructured":"Rommens JM, et al. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science. 1989;245(4922):1059\u201365.","journal-title":"Science"},{"issue":"5","key":"4737_CR5","doi-asserted-by":"publisher","first-page":"L859","DOI":"10.1152\/ajplung.00285.2017","volume":"313","author":"R Bartoszewski","year":"2017","unstructured":"Bartoszewski R, Matalon S, Collawn JF. Ion channels of the lung and their role in disease pathogenesis. Am J Physiol Lung Cell Mol Physiol. 2017;313(5):L859\u201372.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"8","key":"4737_CR6","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/S2213-2600(16)00023-0","volume":"4","author":"K De Boeck","year":"2016","unstructured":"De Boeck K, Amaral MD. Progress in therapies for cystic fibrosis. Lancet Respir Med. 2016;4(8):662\u201374.","journal-title":"Lancet Respir Med"},{"issue":"2","key":"4737_CR7","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1002\/path.4634","volume":"238","author":"KN Gibson-Corley","year":"2016","unstructured":"Gibson-Corley KN, Meyerholz DK, Engelhardt JF. Pancreatic pathophysiology in cystic fibrosis. J Pathol. 2016;238(2):311\u201320.","journal-title":"J Pathol"},{"issue":"5","key":"4737_CR8","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.jcf.2015.06.002","volume":"14","author":"MA Mall","year":"2015","unstructured":"Mall MA, Galietta LJ. Targeting ion channels in cystic fibrosis. J Cyst Fibros. 2015;14(5):561\u201370.","journal-title":"J Cyst Fibros"},{"issue":"2","key":"4737_CR9","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/0016-5085(88)90490-8","volume":"95","author":"H Kopelman","year":"1988","unstructured":"Kopelman H, et al. Impaired chloride secretion, as well as bicarbonate secretion, underlies the fluid secretory defect in the cystic fibrosis pancreas. Gastroenterology. 1988;95(2):349\u201355.","journal-title":"Gastroenterology"},{"issue":"6","key":"4737_CR10","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1056\/NEJM198502073120601","volume":"312","author":"H Kopelman","year":"1985","unstructured":"Kopelman H, et al. Pancreatic fluid secretion and protein hyperconcentration in cystic fibrosis. N Engl J Med. 1985;312(6):329\u201334.","journal-title":"N Engl J Med"},{"issue":"6 Pt 2","key":"4737_CR11","doi-asserted-by":"publisher","first-page":"e109","DOI":"10.1016\/j.lpm.2017.03.021","volume":"46","author":"R Somayaji","year":"2017","unstructured":"Somayaji R, et al. Common clinical features of CF (respiratory disease and exocrine pancreatic insufficiency). Presse Med. 2017;46(6 Pt 2):e109\u201324.","journal-title":"Presse Med"},{"issue":"9","key":"4737_CR12","doi-asserted-by":"publisher","first-page":"a009753","DOI":"10.1101\/cshperspect.a009753","volume":"3","author":"RC De Lisle","year":"2013","unstructured":"De Lisle RC, Borowitz D. The cystic fibrosis intestine. Cold Spring Harb Perspect Med. 2013;3(9):a009753.","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"12","key":"4737_CR13","doi-asserted-by":"publisher","first-page":"a009480","DOI":"10.1101\/cshperspect.a009480","volume":"2","author":"C Ferec","year":"2012","unstructured":"Ferec C, Cutting GR. Assessing the Disease-Liability of mutations in CFTR. Cold Spring Harb Perspect Med. 2012;2(12):a009480.","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"2","key":"4737_CR14","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1085\/jgp.118.2.223","volume":"118","author":"R Tarran","year":"2001","unstructured":"Tarran R, et al. The relative roles of passive surface forces and active ion transport in the modulation of airway surface liquid volume and composition. J Gen Physiol. 2001;118(2):223\u201336.","journal-title":"J Gen Physiol"},{"key":"4737_CR15","unstructured":"Cutting G et al. CFTR2 - Clinical and functional translation of CFTR. 2022. https:\/\/cftr2.org\/about_cftr. Accessed 3 Oct 2022."},{"key":"4737_CR16","unstructured":"Dorfman R et al. Cystic Fibrosis mutation database. http:\/\/www.genet.sickkids.on.ca\/Home.html. Accessed 3 Oct 2022."},{"issue":"10408","key":"4737_CR17","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/S0140-6736(23)01608-2","volume":"402","author":"SY Graeber","year":"2023","unstructured":"Graeber SY, Mall MA. The future of cystic fibrosis treatment: from disease mechanisms to novel therapeutic approaches. Lancet. 2023;402(10408):1185\u201398.","journal-title":"Lancet"},{"key":"4737_CR18","doi-asserted-by":"publisher","first-page":"119889","DOI":"10.1016\/j.cca.2024.119889","volume":"563","author":"K Roe","year":"2024","unstructured":"Roe K. The epithelial cell types and their multi-phased defenses against fungi and other pathogens. Clin Chim Acta. 2024;563:119889.","journal-title":"Clin Chim Acta"},{"issue":"36","key":"4737_CR19","doi-asserted-by":"publisher","first-page":"27947","DOI":"10.1074\/jbc.M002848200","volume":"275","author":"HL Ji","year":"2000","unstructured":"Ji HL, et al. The cytosolic termini of the beta- and gamma-ENaC subunits are involved in the functional interactions between cystic fibrosis transmembrane conductance regulator and epithelial sodium channel. J Biol Chem. 2000;275(36):27947\u201356.","journal-title":"J Biol Chem"},{"issue":"9","key":"4737_CR20","doi-asserted-by":"publisher","first-page":"5310","DOI":"10.1073\/pnas.96.9.5310","volume":"96","author":"R Schreiber","year":"1999","unstructured":"Schreiber R, et al. The first-nucleotide binding domain of the cystic-fibrosis transmembrane conductance regulator is important for Inhibition of the epithelial Na\u2009+\u2009channel. Proc Natl Acad Sci U S A. 1999;96(9):5310\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5225","key":"4737_CR21","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1126\/science.7543698","volume":"269","author":"MJ Stutts","year":"1995","unstructured":"Stutts MJ, et al. CFTR as a cAMP-dependent regulator of sodium channels. Science. 1995;269(5225):847\u201350.","journal-title":"Science"},{"issue":"1","key":"4737_CR22","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1172\/JCI2729","volume":"102","author":"M Mall","year":"1998","unstructured":"Mall M, et al. The amiloride-inhibitable Na\u2009+\u2009conductance is reduced by the cystic fibrosis transmembrane conductance regulator in normal but not in cystic fibrosis airways. J Clin Invest. 1998;102(1):15\u201321.","journal-title":"J Clin Invest"},{"issue":"1\u20132","key":"4737_CR23","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/0014-5793(96)00079-8","volume":"381","author":"M Mall","year":"1996","unstructured":"Mall M, et al. Wild type but not deltaF508 CFTR inhibits Na\u2009+\u2009conductance when coexpressed in xenopus oocytes. FEBS Lett. 1996;381(1\u20132):47\u201352.","journal-title":"FEBS Lett"},{"issue":"22","key":"4737_CR24","doi-asserted-by":"publisher","first-page":"14037","DOI":"10.1074\/jbc.272.22.14037","volume":"272","author":"MJ Stutts","year":"1997","unstructured":"Stutts MJ, Rossier BC, Boucher RC. Cystic fibrosis transmembrane conductance regulator inverts protein kinase A-mediated regulation of epithelial sodium channel single channel kinetics. J Biol Chem. 1997;272(22):14037\u201340.","journal-title":"J Biol Chem"},{"issue":"6","key":"4737_CR25","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1055\/s-0039-1694021","volume":"40","author":"C Bergeron","year":"2019","unstructured":"Bergeron C, Cantin AM. Cystic fibrosis: pathophysiology of lung disease. Semin Respir Crit Care Med. 2019;40(6):715\u201326.","journal-title":"Semin Respir Crit Care Med"},{"key":"4737_CR26","doi-asserted-by":"publisher","unstructured":"Bustamante-Marin XM, Ostrowski LE. Cilia and mucociliary clearance. Cold Spring Harb Perspect Biol. 2017;9. https:\/\/doi.org\/10.1101\/cshperspect.a028241","DOI":"10.1101\/cshperspect.a028241"},{"issue":"6","key":"4737_CR27","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1172\/JCI2687","volume":"102","author":"H Matsui","year":"1998","unstructured":"Matsui H, et al. Coordinated clearance of periciliary liquid and mucus from airway surfaces. J Clin Invest. 1998;102(6):1125\u201331.","journal-title":"J Clin Invest"},{"issue":"2","key":"4737_CR28","doi-asserted-by":"publisher","first-page":"233","DOI":"10.4187\/respcare.06697","volume":"65","author":"NL Turcios","year":"2020","unstructured":"Turcios NL. Cystic fibrosis lung disease: an overview. Respir Care. 2020;65(2):233\u201351.","journal-title":"Respir Care"},{"issue":"1","key":"4737_CR29","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s00018-016-2393-9","volume":"74","author":"C Castellani","year":"2017","unstructured":"Castellani C, Assael BM. Cystic fibrosis: a clinical view. Cell Mol Life Sci. 2017;74(1):129\u201340.","journal-title":"Cell Mol Life Sci"},{"key":"4737_CR30","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.3389\/fphar.2019.01662","volume":"10","author":"M Lopes-Pacheco","year":"2019","unstructured":"Lopes-Pacheco M. CFTR modulators: the changing face of cystic fibrosis in the era of precision medicine. Front Pharmacol. 2019;10:1662.","journal-title":"Front Pharmacol"},{"issue":"6","key":"4737_CR31","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1097\/MCP.0000000000000819","volume":"27","author":"PJ Barry","year":"2021","unstructured":"Barry PJ, Taylor-Cousar JL. Triple combination cystic fibrosis transmembrane conductance regulator modulator therapy in the real world - opportunities and challenges. Curr Opin Pulm Med. 2021;27(6):554\u201366.","journal-title":"Curr Opin Pulm Med"},{"issue":"19","key":"4737_CR32","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","volume":"381","author":"PG Middleton","year":"2019","unstructured":"Middleton PG, et al. Elexacaftor-Tezacaftor-Ivacaftor for cystic fibrosis with a single Phe508del allele. N Engl J Med. 2019;381(19):1809\u201319.","journal-title":"N Engl J Med"},{"issue":"44","key":"4737_CR33","doi-asserted-by":"publisher","first-page":"18825","DOI":"10.1073\/pnas.0904709106","volume":"106","author":"F Van Goor","year":"2009","unstructured":"Van Goor F, et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci U S A. 2009;106(44):18825\u201330.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"4737_CR34","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1056\/NEJMoa1409547","volume":"373","author":"CE Wainwright","year":"2015","unstructured":"Wainwright CE, et al. Lumacaftor-Ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. N Engl J Med. 2015;373(3):220\u201331.","journal-title":"N Engl J Med"},{"issue":"9","key":"4737_CR35","doi-asserted-by":"publisher","first-page":"e20110","DOI":"10.1016\/j.heliyon.2023.e20110","volume":"9","author":"S Allgood","year":"2023","unstructured":"Allgood S, et al. The effect of elexacaftor\/tezacaftor\/ivacaftor on non-pulmonary symptoms in adults with cystic fibrosis. Heliyon. 2023;9(9):e20110.","journal-title":"Heliyon"},{"issue":"5","key":"4737_CR36","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1164\/rccm.202110-2249OC","volume":"205","author":"SY Graeber","year":"2022","unstructured":"Graeber SY, et al. Effects of Elexacaftor\/Tezacaftor\/Ivacaftor therapy on CFTR function in patients with cystic fibrosis and one or two F508del alleles. Am J Respir Crit Care Med. 2022;205(5):540\u20139.","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"4737_CR37","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.3390\/jcm11041021","volume":"11","author":"V Carnovale","year":"2022","unstructured":"Carnovale V et al. Elexacaftor\/Tezacaftor\/Ivacaftor in patients with cystic fibrosis homozygous for the F508del mutation and advanced lung disease: a 48-week observational study. J Clin Med. 2022;11(4):1021. https:\/\/doi.org\/10.3390\/jcm11041021","journal-title":"J Clin Med."},{"key":"4737_CR38","doi-asserted-by":"publisher","first-page":"877118","DOI":"10.3389\/fphar.2022.877118","volume":"13","author":"JG Mainz","year":"2022","unstructured":"Mainz JG, et al. Elexacaftor-Tezacaftor-Ivacaftor treatment reduces abdominal symptoms in cystic Fibrosis-Early results obtained with the CF-Specific CFAbd-Score. Front Pharmacol. 2022;13:877118.","journal-title":"Front Pharmacol"},{"issue":"2","key":"4737_CR39","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.jcf.2022.10.003","volume":"22","author":"SJ Schwarzenberg","year":"2023","unstructured":"Schwarzenberg SJ, et al. Elexacaftor\/tezacaftor\/ivacaftor and Gastrointestinal outcomes in cystic fibrosis: report of promise-GI. J Cyst Fibros. 2023;22(2):282\u20139.","journal-title":"J Cyst Fibros"},{"issue":"3","key":"4737_CR40","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1164\/rccm.202201-0219OC","volume":"206","author":"SY Graeber","year":"2022","unstructured":"Graeber SY, et al. Effects of Elexacaftor\/Tezacaftor\/Ivacaftor therapy on lung clearance index and magnetic resonance imaging in patients with cystic fibrosis and one or two F508del alleles. Am J Respir Crit Care Med. 2022;206(3):311\u201320.","journal-title":"Am J Respir Crit Care Med"},{"issue":"17","key":"4737_CR41","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1056\/NEJMoa1807120","volume":"379","author":"D Keating","year":"2018","unstructured":"Keating D, et al. VX-445-Tezacaftor-Ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles. N Engl J Med. 2018;379(17):1612\u201320.","journal-title":"N Engl J Med"},{"issue":"2","key":"4737_CR42","doi-asserted-by":"publisher","first-page":"2202153","DOI":"10.1183\/13993003.02153-2022","volume":"62","author":"L Schaupp","year":"2023","unstructured":"Schaupp L et al. Longitudinal effects of elexacaftor\/tezacaftor\/ivacaftor on sputum viscoelastic properties, airway infection and inflammation in patients with cystic fibrosis. Eur Respir J. 2023;62(2):2202153. https:\/\/doi.org\/10.1183\/13993003.02153-2022","journal-title":"Eur Respir J."},{"issue":"10","key":"4737_CR43","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1164\/rccm.202209-1653OC","volume":"207","author":"YH Zhou","year":"2023","unstructured":"Zhou YH, et al. Genetic modifiers of cystic fibrosis lung disease severity: Whole-Genome analysis of 7,840 patients. Am J Respir Crit Care Med. 2023;207(10):1324\u201333.","journal-title":"Am J Respir Crit Care Med"},{"issue":"Suppl 1","key":"4737_CR44","doi-asserted-by":"publisher","first-page":"S60","DOI":"10.1016\/j.jcf.2019.11.002","volume":"19","author":"E de Poel","year":"2020","unstructured":"de Poel E, Lefferts JW, Beekman JM. Intestinal organoids for cystic fibrosis research. J Cyst Fibros. 2020;19(Suppl 1):S60\u20134.","journal-title":"J Cyst Fibros"},{"issue":"9","key":"4737_CR45","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1136\/gutjnl-2021-326560","volume":"71","author":"C G\u00fcnther","year":"2022","unstructured":"G\u00fcnther C, et al. Organoids in Gastrointestinal diseases: from experimental models to clinical translation. Gut. 2022;71(9):1892\u2013908.","journal-title":"Gut"},{"issue":"14","key":"4737_CR46","doi-asserted-by":"publisher","first-page":"7905","DOI":"10.3390\/ijms25147905","volume":"25","author":"JM Harper","year":"2024","unstructured":"Harper JM. Primary cell culture as a model system for evolutionary molecular physiology. Int J Mol Sci. 2024;25(14):7905. https:\/\/doi.org\/10.3390\/ijms25147905","journal-title":"Int J Mol Sci."},{"key":"4737_CR47","doi-asserted-by":"publisher","unstructured":"Berical A et al. Generation of airway epithelial cell Air-Liquid interface cultures from human pluripotent stem cells. J Vis Exp. 2022;(184). https:\/\/doi.org\/10.3791\/63882","DOI":"10.3791\/63882"},{"issue":"4","key":"4737_CR48","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.stemcr.2015.02.005","volume":"4","author":"AM Crane","year":"2015","unstructured":"Crane AM, et al. Targeted correction and restored function of the CFTR gene in cystic fibrosis induced pluripotent stem cells. Stem Cell Rep. 2015;4(4):569\u201377.","journal-title":"Stem Cell Rep"},{"issue":"1","key":"4737_CR49","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.stem.2020.09.017","volume":"28","author":"FJ Hawkins","year":"2021","unstructured":"Hawkins FJ, et al. Derivation of airway basal stem cells from human pluripotent stem cells. Cell Stem Cell. 2021;28(1):79\u2013e958.","journal-title":"Cell Stem Cell"},{"issue":"6","key":"4737_CR50","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/j.stemcr.2019.04.014","volume":"12","author":"S Merkert","year":"2019","unstructured":"Merkert S, et al. High-Throughput screening for modulators of CFTR activity based on genetically engineered cystic fibrosis Disease-Specific iPSCs. Stem Cell Rep. 2019;12(6):1389\u2013403.","journal-title":"Stem Cell Rep"},{"issue":"5","key":"4737_CR51","doi-asserted-by":"publisher","first-page":"572","DOI":"10.5966\/sctm.2015-0276","volume":"5","author":"S Simsek","year":"2016","unstructured":"Simsek S, et al. Modeling cystic fibrosis using pluripotent stem Cell-Derived human pancreatic ductal epithelial cells. Stem Cells Transl Med. 2016;5(5):572\u20139.","journal-title":"Stem Cells Transl Med"},{"key":"4737_CR52","doi-asserted-by":"publisher","first-page":"101394","DOI":"10.1016\/j.scr.2019.101394","volume":"35","author":"A Haase","year":"2019","unstructured":"Haase A, et al. GMP-compatible manufacturing of three iPS cell lines from human peripheral blood. Stem Cell Res. 2019;35:101394.","journal-title":"Stem Cell Res"},{"issue":"4","key":"4737_CR53","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.stem.2009.08.021","volume":"5","author":"A Haase","year":"2009","unstructured":"Haase A, et al. Generation of induced pluripotent stem cells from human cord blood. Cell Stem Cell. 2009;5(4):434\u201341.","journal-title":"Cell Stem Cell"},{"issue":"5","key":"4737_CR54","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.cell.2007.11.019","volume":"131","author":"K Takahashi","year":"2007","unstructured":"Takahashi K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131(5):861\u201372.","journal-title":"Cell"},{"issue":"2","key":"4737_CR55","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.jcf.2022.01.008","volume":"21","author":"BL Aalbers","year":"2022","unstructured":"Aalbers BL, et al. Forskolin induced swelling (FIS) assay in intestinal organoids to guide eligibility for compassionate use treatment in a CF patient with a rare genotype. J Cyst Fibros. 2022;21(2):254\u20137.","journal-title":"J Cyst Fibros"},{"key":"4737_CR56","doi-asserted-by":"publisher","first-page":"102918","DOI":"10.1016\/j.scr.2022.102918","volume":"64","author":"MC Jaboreck","year":"2022","unstructured":"Jaboreck MC, et al. Generation of two TMEM16A knockout iPSC clones each from a healthy human iPSC line, from a cystic fibrosis patient specific line with p.Phe508del mutation and from the gene corrected iPSC line. Stem Cell Res. 2022;64:102918.","journal-title":"Stem Cell Res"},{"key":"4737_CR57","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.scr.2017.07.010","volume":"23","author":"S Merkert","year":"2017","unstructured":"Merkert S, et al. Generation of a gene-corrected isogenic control iPSC line from cystic fibrosis patient-specific iPSCs homozygous for p.Phe508del mutation mediated by TALENs and SsODN. Stem Cell Res. 2017;23:95\u20137.","journal-title":"Stem Cell Res"},{"issue":"7","key":"4737_CR58","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.3390\/ijms17071000","volume":"17","author":"S Merkert","year":"2016","unstructured":"Merkert S, Martin U. Site-specific genome engineering in human pluripotent stem cells. Int J Mol Sci. 2016;17(7):1000. https:\/\/doi.org\/10.3390\/ijms17071000","journal-title":"Int J Mol Sci."},{"issue":"2","key":"4737_CR59","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.scr.2016.02.027","volume":"16","author":"S Merkert","year":"2016","unstructured":"Merkert S, Martin U. Targeted genome engineering using designer nucleases: state of the Art and practical guidance for application in human pluripotent stem cells. Stem Cell Res. 2016;16(2):377\u201386.","journal-title":"Stem Cell Res"},{"issue":"1","key":"4737_CR60","doi-asserted-by":"publisher","first-page":"4270","DOI":"10.1038\/s41467-022-31854-8","volume":"13","author":"A Berical","year":"2022","unstructured":"Berical A, et al. A multimodal iPSC platform for cystic fibrosis drug testing. Nat Commun. 2022;13(1):4270.","journal-title":"Nat Commun"},{"issue":"3","key":"4737_CR61","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/nprot.2015.023","volume":"10","author":"SX Huang","year":"2015","unstructured":"Huang SX, et al. The in vitro generation of lung and airway progenitor cells from human pluripotent stem cells. Nat Protoc. 2015;10(3):413\u201325.","journal-title":"Nat Protoc"},{"issue":"1","key":"4737_CR62","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/nbt.2754","volume":"32","author":"SX Huang","year":"2014","unstructured":"Huang SX, et al. Efficient generation of lung and airway epithelial cells from human pluripotent stem cells. Nat Biotechnol. 2014;32(1):84\u201391.","journal-title":"Nat Biotechnol"},{"issue":"4","key":"4737_CR63","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.stem.2017.08.014","volume":"21","author":"A Jacob","year":"2017","unstructured":"Jacob A, et al. Differentiation of human pluripotent stem cells into functional lung alveolar epithelial cells. Cell Stem Cell. 2017;21(4):472\u2013e48810.","journal-title":"Cell Stem Cell"},{"issue":"6","key":"4737_CR64","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.stem.2017.03.001","volume":"20","author":"KB McCauley","year":"2017","unstructured":"McCauley KB, et al. Efficient derivation of functional human airway epithelium from pluripotent stem cells via Temporal regulation of Wnt signaling. Cell Stem Cell. 2017;20(6):844\u2013e8576.","journal-title":"Cell Stem Cell"},{"issue":"3","key":"4737_CR65","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/nprot.2015.021","volume":"10","author":"AP Wong","year":"2015","unstructured":"Wong AP, et al. Efficient generation of functional CFTR-expressing airway epithelial cells from human pluripotent stem cells. Nat Protoc. 2015;10(3):363\u201381.","journal-title":"Nat Protoc"},{"key":"4737_CR66","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.scr.2017.03.022","volume":"21","author":"A Haase","year":"2017","unstructured":"Haase A, G\u00f6hring G, Martin U. Generation of non-transgenic iPS cells from human cord blood CD34(+) cells under animal component-free conditions. Stem Cell Res. 2017;21:71\u20133.","journal-title":"Stem Cell Res"},{"issue":"3","key":"4737_CR67","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.stemcr.2014.07.005","volume":"3","author":"S Gotoh","year":"2014","unstructured":"Gotoh S, et al. Generation of alveolar epithelial spheroids via isolated progenitor cells from human pluripotent stem cells. Stem Cell Rep. 2014;3(3):394\u2013403.","journal-title":"Stem Cell Rep"},{"issue":"6","key":"4737_CR68","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1172\/JCI89950","volume":"127","author":"F Hawkins","year":"2017","unstructured":"Hawkins F, et al. Prospective isolation of NKX2-1-expressing human lung progenitors derived from pluripotent stem cells. J Clin Invest. 2017;127(6):2277\u201394.","journal-title":"J Clin Invest"},{"issue":"11","key":"4737_CR69","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.3390\/cells12111467","volume":"12","author":"L von Schledorn","year":"2023","unstructured":"von Schledorn L et al. Primary ciliary dyskinesia patient-specific hiPSC-derived airway epithelium in air-liquid interface culture recapitulates disease specific phenotypes in vitro. Cells. 2023;12(11):1467. https:\/\/doi.org\/10.3390\/cells12111467","journal-title":"Cells."},{"issue":"1","key":"4737_CR70","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1101\/gad.10.1.60","volume":"10","author":"S Kimura","year":"1996","unstructured":"Kimura S, et al. The T\/ebp null mouse: thyroid-specific enhancer-binding protein is essential for the organogenesis of the thyroid, lung, ventral forebrain, and pituitary. Genes Dev. 1996;10(1):60\u20139.","journal-title":"Genes Dev"},{"issue":"7","key":"4737_CR71","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.3390\/ijms21072386","volume":"21","author":"H Danahay","year":"2020","unstructured":"Danahay H, Gosling M. TMEM16A: an alternative approach to restoring airway anion secretion in cystic fibrosis? Int J Mol Sci. 2020;21(7):2386. https:\/\/doi.org\/10.3390\/ijms21072386","journal-title":"Int J Mol Sci."},{"issue":"5901","key":"4737_CR72","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1126\/science.1163518","volume":"322","author":"A Caputo","year":"2008","unstructured":"Caputo A, et al. TMEM16A, a membrane protein associated with calcium-dependent chloride channel activity. Science. 2008;322(5901):590\u20134.","journal-title":"Science"},{"issue":"1","key":"4737_CR73","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1073\/pnas.1211594110","volume":"110","author":"J Jung","year":"2013","unstructured":"Jung J, et al. Dynamic modulation of ANO1\/TMEM16A HCO3(-) permeability by Ca2+\/calmodulin. Proc Natl Acad Sci U S A. 2013;110(1):360\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7718","key":"4737_CR74","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/s41586-018-0393-7","volume":"560","author":"DT Montoro","year":"2018","unstructured":"Montoro DT, et al. A revised airway epithelial hierarchy includes CFTR-expressing ionocytes. Nature. 2018;560(7718):319\u201324.","journal-title":"Nature"},{"issue":"7718","key":"4737_CR75","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/s41586-018-0394-6","volume":"560","author":"LW Plasschaert","year":"2018","unstructured":"Plasschaert LW, et al. A single-cell atlas of the airway epithelium reveals the CFTR-rich pulmonary ionocyte. Nature. 2018;560(7718):377\u201381.","journal-title":"Nature"},{"issue":"2","key":"4737_CR76","doi-asserted-by":"publisher","first-page":"2100671","DOI":"10.1183\/13993003.00671-2021","volume":"59","author":"F Becq","year":"2022","unstructured":"Becq F et al. The rescue of F508del-CFTR by elexacaftor\/tezacaftor\/ivacaftor (Trikafta) in human airway epithelial cells is underestimated due to the presence of Ivacaftor. Eur Respir J. 2022;59(2):2100671. https:\/\/doi.org\/10.1183\/13993003.00671-2021","journal-title":"Eur Respir J."},{"key":"4737_CR77","doi-asserted-by":"publisher","first-page":"1114584","DOI":"10.3389\/fphar.2023.1114584","volume":"14","author":"F Stanke","year":"2023","unstructured":"Stanke F, et al. Changes in cystic fibrosis transmembrane conductance regulator protein expression prior to and during elexacaftor-tezacaftor-ivacaftor therapy. Front Pharmacol. 2023;14:1114584.","journal-title":"Front Pharmacol"},{"issue":"19","key":"4737_CR78","doi-asserted-by":"publisher","first-page":"14539","DOI":"10.3390\/ijms241914539","volume":"24","author":"JW Lefferts","year":"2023","unstructured":"Lefferts JW et al. CFTR function restoration upon elexacaftor\/tezacaftor\/ivacaftor treatment in patient-derived intestinal organoids with rare CFTR genotypes. Int J Mol Sci. 2023;24(19):14539. https:\/\/doi.org\/10.3390\/ijms241914539","journal-title":"Int J Mol Sci."},{"key":"4737_CR79","doi-asserted-by":"publisher","first-page":"693","DOI":"10.2147\/JEP.S255377","volume":"13","author":"MC Pinto","year":"2021","unstructured":"Pinto MC, et al. Pharmacological modulation of ion channels for the treatment of cystic fibrosis. J Exp Pharmacol. 2021;13:693\u2013723.","journal-title":"J Exp Pharmacol"},{"issue":"7","key":"4737_CR80","doi-asserted-by":"publisher","first-page":"L593","DOI":"10.1152\/ajplung.00321.2015","volume":"310","author":"JJ Salomon","year":"2016","unstructured":"Salomon JJ, et al. Generation and functional characterization of epithelial cells with stable expression of SLC26A9 Cl- channels. Am J Physiol Lung Cell Mol Physiol. 2016;310(7):L593\u2013602.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"4737_CR81","doi-asserted-by":"publisher","first-page":"100690","DOI":"10.1016\/j.lanepe.2023.100690","volume":"32","author":"S Sutharsan","year":"2023","unstructured":"Sutharsan S, et al. Impact of elexacaftor\/tezacaftor\/ivacaftor on lung function, nutritional status, pulmonary exacerbation frequency and sweat chloride in people with cystic fibrosis: real-world evidence from the German CF registry. Lancet Reg Health Eur. 2023;32:100690.","journal-title":"Lancet Reg Health Eur"},{"issue":"16","key":"4737_CR82","doi-asserted-by":"publisher","DOI":"10.1172\/JCI176328","volume":"134","author":"A Kolski-Andreaco","year":"2024","unstructured":"Kolski-Andreaco A et al. Potentiation of BKCa channels by cystic fibrosis transmembrane conductance regulator correctors VX-445 and VX-121. J Clin Invest. 2024;134(16):e176328. https:\/\/doi.org\/10.1172\/JCI176328","journal-title":"J Clin Invest."},{"issue":"1","key":"4737_CR83","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1186\/s12931-024-03059-8","volume":"25","author":"M L\u00e9v\u00eaque","year":"2024","unstructured":"L\u00e9v\u00eaque M, et al. The F508del-CFTR trafficking correctors Elexacaftor and Tezacaftor are CFTR-independent Ca(2+)-mobilizing agonists normalizing abnormal Ca(2+) levels in human airway epithelial cells. Respir Res. 2024;25(1):436.","journal-title":"Respir Res"},{"issue":"4","key":"4737_CR84","doi-asserted-by":"publisher","first-page":"100988","DOI":"10.1016\/j.xpro.2021.100988","volume":"2","author":"F Manstein","year":"2021","unstructured":"Manstein F, et al. Process control and in Silico modeling strategies for enabling high density culture of human pluripotent stem cells in stirred tank bioreactors. STAR Protoc. 2021;2(4):100988.","journal-title":"STAR Protoc"},{"issue":"5","key":"4737_CR85","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/nprot.2011.318","volume":"6","author":"R Zweigerdt","year":"2011","unstructured":"Zweigerdt R, et al. Scalable expansion of human pluripotent stem cells in suspension culture. Nat Protoc. 2011;6(5):689\u2013700.","journal-title":"Nat Protoc"},{"issue":"2","key":"4737_CR86","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.stem.2016.05.012","volume":"19","author":"H Mou","year":"2016","unstructured":"Mou H, et al. Dual SMAD signaling Inhibition enables Long-Term expansion of diverse epithelial basal cells. Cell Stem Cell. 2016;19(2):217\u201331.","journal-title":"Cell Stem Cell"},{"key":"4737_CR87","doi-asserted-by":"publisher","first-page":"822437","DOI":"10.3389\/fimmu.2022.822437","volume":"13","author":"A Bal\u00e1zs","year":"2022","unstructured":"Bal\u00e1zs A, et al. Age-Related differences in structure and function of nasal epithelial cultures from healthy children and elderly people. Front Immunol. 2022;13:822437.","journal-title":"Front Immunol"},{"issue":"15","key":"4737_CR88","doi-asserted-by":"publisher","first-page":"12365","DOI":"10.3390\/ijms241512365","volume":"24","author":"SY Graeber","year":"2023","unstructured":"Graeber SY et al. Personalized CFTR modulator therapy for G85E and N1303K homozygous patients with cystic fibrosis. Int J Mol Sci. 2023;24(15):12365. https:\/\/doi.org\/10.3390\/ijms241512365","journal-title":"Int J Mol Sci."},{"issue":"Pt 2","key":"4737_CR89","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1046\/j.1365-2818.2003.01209.x","volume":"211","author":"JH Sisson","year":"2003","unstructured":"Sisson JH, et al. All-digital image capture and whole-field analysis of ciliary beat frequency. J Microsc. 2003;211(Pt 2):103\u201311.","journal-title":"J Microsc"}],"container-title":["Stem Cell Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-025-04737-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13287-025-04737-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-025-04737-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:09:18Z","timestamp":1761127758000},"score":1,"resource":{"primary":{"URL":"https:\/\/stemcellres.biomedcentral.com\/articles\/10.1186\/s13287-025-04737-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,21]]},"references-count":89,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4737"],"URL":"https:\/\/doi.org\/10.1186\/s13287-025-04737-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7184232\/v1","asserted-by":"object"}]},"ISSN":["1757-6512"],"issn-type":[{"value":"1757-6512","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,21]]},"assertion":[{"value":"22 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Human anonymized blood samples for generation of hiPSCs were collected based on the approvals by the Hannover Medical School (MHH) Ethics Committee (No. 409; approval date: 21.09.2010) as part of the project \u2018Nutzung von anonymisierten Patientenzellen f\u00fcr die biomedizinische Forschung \/ Generierung von induzierten pluripotenten Stammzellen\u2019 and following the donor\u2019s written informed consent, or in the case of newborns, following parental consent. Human anonymized explanted lung tissue samples for isolation of primary bronchial epithelial cells were collected based on the approvals by the Hannover Medical School (MHH) Ethics Committee (No. 10194_BO_K_2022) as part of the project \u2018Humane Gewebe- und prim\u00e4re Zellkultur als ex vivo Modelle f\u00fcr die Analyse von end-stage lung disease Lungen und Lungentumoren\u2019 and following the donor\u2019s written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"573"}}